ASH 2023 | Addressing cardiovascular AEs associated with BTKi treatment in patients with CLL
Lee Greenberger
• 9 Dec 2023
Lee Greenberger, PhD, Leukemia & Lymphoma Society, New York, NY, addresses cardiovascular adverse events (AEs) related to BTK inhibitors (BTKi) in the treatment of patients with chronic lymphocytic leukemia (CLL). There are multiple BTKi available, including those with lower cardiovascular toxicity, such as acalabrutinib and zanubrutinib, so physicians have various avenues to ensure the benefits of BTKi treatment are optimized. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
